anticoagulation - search results
If you're not happy with the results, please do another search
Trial supports full-dose anticoagulation to prevent blood clots in COVID-19 patients
Treatment of critically ill COVID-19 patients with full-dose anticoagulation lowers the risk of venous and arterial clotting complications by 44% compared with the standard...
Biomarkers of heart failure show early reversal with catheter thrombolysis compared to anticoagulation alone...
In a secondary analysis of the SUNSET sPE randomised controlled trial, Efthymios Avgerinos (University of Pittsburgh Medical Centre, Pittsburgh, USA) and colleagues found differences...
SVT patients bear “significant risk” of thromboembolic complications at three months, despite anticoagulation
Despite a high rate of initial anticoagulation, patients with isolated superficial vein thrombosis (SVT) are at risk of thromboembolic complications—including recurrent or extended SVT...
Thrombosis is major by-product of infection with COVID-19, but evidence to back full dose...
Manj Gohel (Cambridge, UK), one of the editors-in-chief of Venous News, introduces a special COVID-19 video with leading thrombosis and haemostasis experts, including Beverley...
No difference in PE incidence between patients treated with IVC filters or anticoagulation alone
In a case-control study of patients with perceived contraindications to anticoagulation, who either received or did not receive inferior vena cava (IVC) filters, no...
Paediatric trial finds rivaroxaban similar to standard anticoagulation in treatment of VTE
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 EINSTEIN-Jr study, showing paediatric patients (aged birth to...
RSM thrombosis and anticoagulation conference
W: www.rsm.ac.uk
More bleeding with catheter-directed thrombolysis than with standard anticoagulation in deep vein thrombosis
A study published in the Journal of the American Medical Association (JAMA) has found no difference in mortality rates between deep vein thrombosis patients...
Ultrasound-accelerated thrombolysis shows advantage over anticoagulation alone in submassive pulmonary embolism
Results of the ULTIMA pulmonary embolism trial comparing endovascular therapy to standard of care were presented at the American College of Cardiology meeting in...
FLAME, FLASH and ongoing PEERLESS trials collect “compelling” data for FlowTriever device
Speaking on the FLAME, FLASH and PEERLESS trials that each collected data on the FlowTriever (Inari Medical) device for the treatment of pulmonary embolism...
Why might CLOUT and DEFIANCE open the door to a new generation of data...
Steven Abramowitz (Washington DC, USA) explains the significance of the CLOUT registry—the only registry capturing data on mechanical thrombectomy in deep venous thrombosis (DVT)....
SCAI 2023: Mechanical thrombectomy improves symptoms and quality of life in pulmonary embolism patients...
Six-month outcomes from the FLASH registry have shown that patients with pulmonary embolism who were treated with mechanical thrombectomy showed significant improvement in symptoms,...
Primary patency after venous stenting best in NIVL patients, study finds
A recent study concludes that non-thrombotic iliac vein lesion (NIVL) patients have better primary patency after venous stenting than patients with venous thrombotic disorders....
Viz.ai to expedite patient enrolment in NIH-funded PE-TRACT clinical trial
Viz.ai has announced it will use its Viz Recruit platform to optimise patient enrolment for the National Institutes of Health (NIH)-funded Pulmonary embolism—thrombus removal...
AVF 2023: Investigators report update on three-year first-in-human results for bioprosthetic venous valve
Researchers in Colombia behind the first-in-human study of a novel bioprosthetic venous valve designed to treat chronic venous insufficiency (CVI) reported three-year results among...
New study demonstrates IVC filters “safe and effective” in treating venous thromboembolism
Few adverse events are connected to the use of inferior vena cava (IVC) filters to help prevent deep vein blood clots from developing into...
Educate, educate, and educate again: The continuing quest for appropriate venous care
Prominent venous disease experts discuss venous stenting, appropriate care, and the pursuit of refined data and better education in a space where part of...
Inari Medical announces first patient enrolment in DEFIANCE trial of the ClotTriever system in...
Inari Medical has announced that the first patient has been enrolled in DEFIANCE, a prospective randomised controlled trial (RCT) comparing the clinical outcomes of...
Analysis of varicose vein registry finds women benefit from endovenous ablation with fewer complications
An evaluation of the Vascular Quality Initiative’s (VQI) Varicose Vein Registry (VVR) carried out by the Midwestern Vascular Surgical Society (MVSS) has found women...
Meta-analysis of PTS finds one in five risk of long-term symptoms following isolated distal...
A meta-analysis is first to report the pooled risk of post-thrombotic syndrome (PTS) after isolated distal deep vein thrombosis (DVT). Researchers revealed a one...
First-in-human patients continue to benefit from VenoValve at average of three years post-surgery, new...
Positive long-term, three-year observational data from a cohort of patients that participated in the previously concluded VenoValve (Envveno Medical) first-in-human clinical trial were recently...
SIR deems endovascular management acceptable treatment option for certain iliofemoral DVT patients
The Society of Interventional Radiology (SIR) published a position statement deeming endovascular thrombus removal “an acceptable treatment option in selected patients with acute iliofemoral...
Mechanical thrombectomy for DVT: Randomised data needed to boost growing evidence base
Two datasets presented during the late-breaking clinical trials session at The VEINS (Venous Endovascular Interventional Strategies) 2022 (30–31 October, Las Vegas, USA)—the latest results...
New mechanical thrombectomy systems unlock possibilities for the treatment of venous thromboembolism
Gerd Grözinger (Tübingen, Germany) chats with Bernhard Gebauer (Berlin, Germany) at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting (10–14...
Inari Medical announces randomised controlled trial evaluating clinical outcomes of the ClotTriever system in...
Inari Medical has announced planned enrolment of the DEFIANCE randomised controlled trial (RCT), which is designed to compare the clinical outcomes of patients with...
VTE: Fewer recurrences with low-dose apixaban compared to discontinuation of the anticoagulant after negative...
Patients who have suffered from a first episode of unprovoked venous thromboembolism (VTE) have an eight times higher risk of recurrence if they stop...
“Excellent outcomes” for Zilver Vena® venous stent sustained out to three years in challenging...
This advertorial is sponsored by Cook Medical. A downloadable version can be found here.
The Zilver Vena venous self-expanding stent system (Cook Medical) is associated...
Contemporary venous intervention reduces post-thrombotic syndrome in initial CLEAR-DVT analysis
In an initial cohort of patients enrolled in the CLEAR-DVT study, contemporary venous intervention resulted in an open vein, which reduced post-thrombotic syndrome (PTS)....
Anticoagulants effective for pulmonary embolism resolution in hospitalised COVID-19 patients
Anticoagulants alone are associated with a high rate of resolution of pulmonary embolism (PE) in patients with acute PE and COVID-19 infection. This was...
Venous stents remain durable following pregnancy
Iliac vein stents tolerate a gravid uterus well and a possible future pregnancy should not contraindicate their usage in the treatment of pelvic venous...
Blueflow venous stent for chronic iliofemoral venous disease “offers favourable primary patency”
Deep venous stenting with the Blueflow venous stent (Plus Medica) offers favourable primary patency, and is associated with significant continued improvement of symptom severity...
FDA approves two paediatric venous thromboembolism indications for Janssen’s Xarelto
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that the US Food and Drug Administration (FDA) has approved two paediatric indications for...
Recommendation for repeat imaging after incomplete ultrasound exam increases follow-up rate
The rate of follow-up after an incomplete and negative lower extremity venous duplex ultrasound (I/N LEVDUS) has been shown to increase following a specific...
CHEST releases new guidelines for antithrombotic therapy for VTE disease
The American College of Chest Physicians (CHEST) recently released new clinical guidelines for venous thromboembolism (VTE) management, “Antithrombotic therapy for VTE disease: Second update...
Boston Scientific initiates randomised controlled trial for the EkoSonic endovascular system
Boston Scientific has commenced enrolment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the...
Case report: Recanalisation of chronic iliofemoral venous occlusion in a patient with PAD and...
This advertorial, sponsored by BD, is only available in selected countries and geographies.
A downloadable version of this advertorial can be found here.
In this...
Janssen submits new drug application to US FDA for Xarelto (rivaroxaban) to help prevent...
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced it has submitted a new drug application (NDA) to the US Food and Drug...
Recent advances in VTE management provide much-needed clarity, but more needs to be done
Manjit Gohel (Cambridge, UK) and Stephen Black (London, UK) write that several recent advances in the management of venous thromboembolism (VTE) have provided clarity...
Further research will soon generate standardised approach to VTE in COVID-19 patients
At VENOUS2021 (17–20 March, virtual), the annual meeting of the American Venous Forum, Geno Merli (Thomas Jefferson University Hospital, Philadelphia, USA) gave a keynote...
What an interventionalist needs to know about DOACs in 2021
The publication of positive new data and a need to minimise hospital visits during the COVID-19 pandemic has seen a general trend towards using...
Towards universal adoption: Development of the AVF and SVS EHIT guidelines
While various treatment regimens for the “unique complication” of endothermal heat-induced thrombosis (EHIT) following endovenous ablation have been developed, Lowell S Kabnick tells Venous...
Interview: Comprehensive, patient-friendly risk assessment “crucial” to VTE prevention
From the first research linking heparin to a reduction in fatal pulmonary embolism (PE), to the development and refinement of risk assessment tools to...
High thrombotic risk in cancer patients receiving immunotherapy
According to a recent study, patients with cancer under immune checkpoint inhibitor therapy are at high risk of thromboembolism, especially venous thromboembolism (VTE). Furthermore,...
Outpatient-based warfarin monitoring programme safely adapts to COVID-19 challenges
Faced with a need to limit hospital visits and conserve personal protective equipment (PPE) in the wake of COVID-19, an 11-centre, hospital-based anticoagulation monitoring...
High rate of early reocclusion in patients who require recanalisation of occluded venous outflow...
A new study has found that patients who require recanalisation of a completely occluded venous outflow tract before stenting have a high rate of...
Meta-analysis: IVC filters should be considered for certain patients at high risk of PE
In a recent meta-analysis, Yang Liu, Huan Lu (Henan Cancer Hospital, Zhengzhou, China), and colleagues found insufficient evidence to prove that inferior vena cava...
Bayer receives approval in the UK for Xarelto to treat and prevent recurrence of...
Bayer has received approval in the UK for the use of its oral Factor Xa inhibitor Xarelto (rivaroxaban) to treat venous thromboembolism (VTE) and...
VTE management in COVID-19: “Use evidence-based prophylaxis and enrol patients in a clinical trial”
Venous thromboembolism (VTE) in COVID-19 patients was a key topic on the agenda of The VEINS (Venous Endovascular INterventional Strategies) session at VIVA 2020...
A multidisciplinary approach to VTE in COVID-19 patients is warranted
The nature of venous thromboembolism (VTE) in COVID-19 patients is complex, and treatment strategies regarding drug type and dosing continue to evolve, writes Sanjum...
First ESVS guidelines on venous thrombosis published
The European Society for Vascular Surgery (ESVS) has produced a clinical practice guidelines document on the management of venous thrombosis—the first guidelines the society...
First-in-human study finds novel laser technique “safe and effective” for embedded filter removal
The excimer laser sheath technique is safe and effective for removing embedded inferior vena cava (IVC) filters refractory to high-force retrieval, the investigators of...
DIVERSITY trial finds adjusted dabigatran dosing algorithm appropriate for treatment of VTE in children
In a recent randomised controlled trial, an age-adjusted, weight-adjusted dabigatran dosing algorithm was found to be appropriate in children under 18 years old with...
Comparable risk of recurrent VTE between patients with unprovoked VTE and patients with cancer
Patients with venous thromboembolism (VTE) carry a high risk of recurrence. Accordingly, a 16-year Danish prospective cohort study of nearly 74,000 patients with incident VTE...
Intracranial haemorrhage rare in patients treated with catheter-directed thrombolysis for proximal DVT, study finds
In a recent nationwide study of observational data from the USA, intracranial haemorrhage (ICH) was found to be rare among deep vein thrombosis (DVT)...
Society of Interventional Radiology publishes IVC filter guidelines
The Society of Interventional Radiology (SIR) recently published new clinical practice guidelines that provide evidence-based recommendations on the use of inferior vena cava (IVC)...
Rivaroxaban associated with reduced risk of recurrent VTE versus warfarin in patients with obesity
In a study evaluating rivaroxaban (Xarelto; Bayer) versus warfarin for the treatment and prevention of recurrent venous thromboembolism (VTE) in patients with obesity, results...
Women are at a higher risk of iliac vein stent failure
A recent study on iliac vein stenting showed lower long-term patency rates for women when compared to their male counterparts. The data were presented...
COVID-19 will have “massive long-term impact” on treatment of venous disease patients
Manj Gohel (Cambridge, UK) is joined by a host of venous experts including Beverley Hunt (London, UK), Stephen Black (London, UK) and Ian Franklin...
CX 2020 LIVE addresses latest developments in superficial venous disease
For the first venous session of CX 2020 LIVE, 759 attendees from 79 different countries tuned in. Each audience member could submit their name,...
New study shows COVID-19 causes severe blood vessel damage
New research published in the New England Journal of Medicine shows that the respiratory virus SARS-CoV-2, which causes COVID-19, causes severe damage to blood...
At six months, adjunctive mechanical thrombectomy associated with higher patency and lower incidence of...
A recent systematic review and meta-analysis showed that, in patients with iliofemoral deep vein thrombosis (DVT), percutaneous mechanical thrombectomy was associated with a higher...
Geko device represents an alternative to IPC devices during COVID-19
Sky Medical Technology highlights a publication on 5 May 2020 in the Journal of Thrombosis and Haemostasis showing the incidence of venous thromboembolism (VTE) in...
A Deeper Dive into the Venovo™ Venous Stent System
Venous News talks with Gerard O'Sullivan, FSIR, FEBIR, University College Hospital, Galway, Ireland. This article is supported by BD Interventional.
Disclosures: Dr. Gerard O'Sullivan reports...
AVF releases white paper on considerations in prophylaxis and treatment of VTE in COVID-19...
The COVID-19 subcommittee of the American Venous Forum (AVF) has issued a white paper on considerations in prophylaxis and treatment of venous thromboembolism (VTE)...
COVID-19: Reflections on VTE, patient risk assessment, and therapeutic challenges
Joseph A Caprini considers venous thromboemolism (VTE), patient risk assessment, and therapeutic challenges in the wake of the COVID-19 pandemic, concluding that "accurate thrombosis...
COVID-19: what will be the fallout for patients with venous disease?
Manj Gohel, Stephen Black and Alun Davies consider the impact of the COVID-19 pandemic on patients with venous disease. They conclude: "Once the acute...
Early results of endovenous valve formation study confirm feasibility for treatment of deep vein...
Results of a 12-month study conducted by a group of Commonwealth physicians have demonstrated that endovenous valve formation in the deep venous system is...
Deep venous stenting presents advantage over ablation in achieving better ulcer healing rates
“Venous leg ulcers (VLUs) secondary to deep venous stenosis represents a distinct class of patients who require a unique treatment paradigm,” stated Abhisekh Mohapatra...
Examining the viability of interventional treatment for iliofemoral DVT
ATTRACT compared outcomes following pharmacomechanical thrombolysis (PMT) versus standard medical therapy (SMT), and while no benefit with PMT was demonstrated for femoropopliteal deep vein...
Review of clot removal system shows positive short-term outcomes for lower extremity DVT treatment
Use of the ClotTreiver system (Inari Medical) for the treatment of lower extremity deep vein thrombosis (DVT) has demonstrated safety and efficacy, especially in...
Reviewing evidence for and against IVC filters in 2020
Following the publication of “Another nail in the coffin of vena cava filters” in the British Journal of Surgery, which considered potential problems with...
Initial results from first-in-man trial of prosthetic VenoValve demonstrate promise
Initial results of an ongoing first-in-man study in Colombia, that saw the implantation of a prosthetic venous valve in 15 patients, have demonstrated an...
Where does the CAVA trial leave early thrombus removal for iliofemoral DVT?
Results from the Dutch CAVA trial were published recently in The Lancet Haematology and, at first glance, this is another trial that failed to...
Astronaut study highlights risk of blood clots in the internal jugular vein during spaceflight
Serena Auñón-Chancellor, clinical associate professor of medicine at Louisiana State University Health, New Orleans School of Medicine’s branch campus, in Baton Rouge, USA, is...
ATTRACT analysis finds improved quality of life for iliofemoral DVT patients treated with PCDT
An analysis of data from the ATTRACT trial, published in the Journal of Vascular Surgery: Venous and Lymphatic Disorders (JVSVL), reveals that quality of...
First pulmonary embolism patient treated with “cyclical” aspiration system
Insera Therapeutics’ CLEAR aspiration system has been used for the first time to treat a (human) patient with acute pulmonary embolism (PE). CLEAR, “cyclical...
New trial planned to rigorously test catheter-directed thrombolysis for submassive PE treatment
Clinically relevant outcomes are needed to measure catheter-directed therapy (CDT) against anticoagulation alone to treat submassive pulmonary embolism (PE) patients. Further, CDT’s ability to...
EXTRACT-PE trial of aspiration thrombectomy for acute pulmonary embolism meets efficacy and safety endpoints
It has been found by the EXTRACT-PE trial, a multicentre investigation conducted under an investigational device exemption (IDE) from the US Food and Drug...
Most reinterventions following treatment of iliofemoral DVT could be due to “preventable factors”
Analysing the results of a retrospective, single-centre cohort study conducted at Guys and St Thomas’ Hospital, London, UK, Anna Pouncey (Guys and St Thomas’...
Future trials on the management of DVT “have to focus on technical success” following...
Speaking at the annual meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE 2019; 7–11 September, Barcelona, Spain), Stephen Black (Guys and...
Improved instruments required for classification of chronic venous disease
Current classification tools for the diagnosis of chronic venous disease, including acute deep vein thrombosis (DVT) and post-thrombotic syndrome (PTS), include “redundant” elements that...
A look at new preliminary guidelines for superficial vein thrombosis
At the European Society of Vascular Surgery annual meeting (ESVS 2019; 24-27 September, Hamburg, Germany), preliminary venous thrombosis guidelines were presented for the first...
RE-SPECT trial establishes efficacy of Pradaxa for treatment of CVT patients
Boehringer Ingelheim has announced the publication of primary analysis from RE-SPECT CVT, the first exploratory, prospective, randomised controlled study of a NOAC in patients...
Updated VTE treatment guideline for patients with cancer revealed by ASCO
An updated guideline on the prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer has been unveiled by the American Society of...
Thrombophilia not an independent risk factor for venous stent patency loss or reintervention
A recent study has concluded that patients with inherited or acquired thrombophilia should not be excluded from ilio-femoral venous stenting, Adam Gwozdz (St Thomas’...
SUNSET sPE thrombolysis trial presents interim analysis of ultrasound-guided versus standard catheter thrombolysis for...
The Standard vs ultrasound-assisted catheter thrombolysis for submassive pulmonary embolism (SUNSET sPE) trial, is an ongoing randomised, head-to-head, single-blinded clinical trial comparing ultrasound-assisted thrombolysis...
Increased risk of VTE found in critically ill H1N1 patients with acute respiratory distress
A new study has found that intensive care unit patients with swine flu (H1N1) and acute respiratory distress syndrome (ARDS) were 33 times more...
High-intensity focused ultrasound system provides noninvasive treatment of venous insufficiency in feasibility study
A new treatment modality is aiming to take the idea of minimally-invasive procedures to the next level for treatment of varicose veins and venous...
The optimal pathway for acute deep vein thrombosis treatment involves identification, management and surveillance
Prakash Saha (London, UK), speaking during the Venous and Lymphatic Challenges programme at CX (15–18 April, London, UK), outlined the three key steps to...
Endpoints for first-in-human VenoValve study announced by Hancock Jaffe
Medical device company Hancock Jaffe has announced the end-points for its upcoming VenoValve first-in-human study in Bogota, Colombia. Endpoints for the study will include...
New DVT device completes first-in-human trial
The first-in-human case using the new deep vein thrombosis (DVT) device Vetex thrombectomy catheter (Vetex Medical) has recently been completed in a multicentre study....
New ATTRACT data show catheter-based therapy significantly reduces leg symptoms and PTS severity to...
A new study, recently published online in the journal Circulation, reports on outcomes from a subgroup of 391 patients with acute iliofemoral deep venous...
Ramesh Tripathi
Having worked as a vascular surgeon and venous specialist in several different countries and continents, Ramesh Tripathi has a wide-ranging experience and storied career. He...
Kathleen Gibson
An accomplished vascular surgeon and prominent clinical researcher in the venous field, Kathleen Gibson (Lake Washington Vascular Surgeons, Bellevue, USA) plays an active role...
AngioJet thrombectomy can reduce dose and duration of lysis compared to thrombolysis alone
Anna Louise Pouncey revealed at the European Venous Forum annual meeting (EVF; 28–30 June, Athens, Greece) the findings of the GSTT venous team (Guy’s...
Current aspects in the management of superficial vein thrombosis
Superficial vein thrombosis is not a rare disease, with an incidence of 0.64 in 1,000 annually.1 The POST, OPTIMEV and STEPH studies have shown...
New intravascular ultrasound-based scoring system may predict future venous stent failure
To accompany the growing importance of intravascular ultrasound (IVUS) as an adjuvant diagnostic tool when treating deep venous disease, a study sought to create...
Early identification of patients at high risk for iliofemoral DVT needs improvement
According to Fedor Lurie (Jobst Vascular Institute, Toledo, USA), who presented at the European Venous Forum Annual Meeting (EVF; 28–30 June, Athens, Greece), patients...
One-year results of ACCESS PTS study brings “hope” for post-thrombotic syndrome patients
The one-year results of the ACCESS PTS trial have shown that EKOS therapy (BTG) statistically improves post-thrombotic syndrome scores and sequelae as well as...
CX audience rejects idea that ATTRACT has the final say on thrombolysis in deep...
According to a debate at the Charing Cross Symposium (CX; 24–27 April, London, UK), the vast majority of CX delegates disagree with the view...
Reviewing five years of deep venous stenting: What comes next?
For many venous specialists, dedicated venous stents represent the future—and the promise of an ideal venous stent on the horizon is a central topic...
Use of IVUS to optimise outcomes in venous stenting
Intravascular ultrasound (IVUS) imaging technology provides the current gold standard technique for detection and characterisation of venous disease, Erin Murphy writes. In this article,...
UIP audience votes against stenting as standard for deep vein obstruction
The deep venous world is wrestling with the question: To stent or not to stent. While the availability of new specialised venous stents is...
High lysis completeness “guarantees high success rates” of iliac vein stent patency following acute...
A recent study on iliac vein stenting following catheter-directed thrombolysis for deep vein thrombosis (DVT) has shown that technical and clinical success require high...
Armando Mansilha
Armando Mansilha is professor of Angiology and Vascular Surgery, Faculty of Medicine at the University of Porto, Porto, Portugal. In this interview with Venous...
Published ATTRACT data call into question validity of the Villalta scale
Following the publication of the ATTRACT trial in the New England Journal of Medicine (NEJM) in December 2017, Venous News spoke to experts in...
VQI Varicose Vein Registry: A tool to help guide decision-making at the patient and...
Members of the venous community have had a longstanding commitment to collecting and analysing the outcomes of venous procedures. The Vascular Quality Initiative (VQI)...
Study to measure shorter duration EKOS therapy for pulmonary embolism is enrolling
Global specialist healthcare company BTG has highlighted the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how hospitals and patients...
Identifying standard practices of antithrombotic therapy post-venous stenting
Venous stenting has evolved over the last 15 years, quickly becoming an established procedure, with Class II recommendations from the American Heart Association and...
Considering venous thrombosis at unusual sites
At the THE VEINS at VIVA meeting (10–11 September, Las Vegas, USA), Esther Kim (Vanderbilt University Medical Center, Nashville, USA) gave a presentation on venous thrombosis...
Superficial venous thrombosis: Ultrasound, analysis of clot location, and risk factor assessment are “fundamental”
At THE VEINS at VIVA meeting (10–11 September 2017, Las Vegas, USA), James Froehlich, University of Michigan, Ann Arbor, USA, reviewed guidelines on the management of...
IVC filter moratorium “not in the best interests of our patients”
Inferior vena cava (IVC) filters have been a highly controversial topic in the field of venous medicine due to the high rates of complications associated with...
FDA approves new 10mg dosing for rivaroxaban to reduce continued risk of VTE
Janssen Pharmaceuticals has announced that the FDA has approved the 10mg once-daily dose of rivaroxaban (Xarelto) for reducing the continued risk for recurrent venous...
Decision-making in the choice of anticoagulants following deep venous stenting
Deep venous stenting has become increasingly used to treat patients with pathological obstruction of venous return in the femoro-iliocaval venous segment following the development of new...
First European advice on deep vein thrombosis published in European Heart Journal
The first comprehensive European advice on deep vein thrombosis was recently published in the European Heart Journal. The recommendations were produced by the European...
Thrombosis: Both a physical and psychological event
There are two things you need to know about me. Firstly, I am a health psychologist, with a specialist interest in behaviour change, implementation, and impact....
One-year SENTRY trial data offer a “a new perspective” on IVC filters
Twelve-month results from the SENTRY trial evaluating the Sentry bioconvertible inferior vena cava (IVC) filter (Novate) have shown a 0% rate of symptomatic pulmonary...
GARFIELD-VTE Registry sheds light on global heterogeneity of venous thromboembolism patients, treatment and outcomes
The first results from the GARFIELD-VTE (Global anticoagulant registry in the field—venous thromboembolism) were presented at the International Society on Thrombosis and Haemostasis Congress...
Angel Catheter demonstrates reduction in clinically-significant and fatal pulmonary embolism
Bio2 Medical has announced the results of the Angel Catheter pivotal study published in the Journal of Vascular and Interventional Radiology. The Angel Catheter...
FDA grants priority review of Xarelto for a 10mg dose to reduce recurrent VTE...
The US Food and Drug Administration (FDA) has accepted, for priority review, a supplemental new drug application (sNDA) for Janssen’s Xarelto (rivaroxaban), to include...
ACCESS PTS study demonstrates efficacy of EKOS therapy for post-thrombotic syndrome
The results of the ACCESS PTS trial have been presented at the Society for Vascular Medicine 28th Annual Scientific Sessions (14–17 June, New Orleans,...
OPTALYSE PE study demonstrates safety and efficacy of shorter, lower dose EKOS therapy for...
Results from the OPTALYSE PE trial have been presented at the American Thoracic Society International Conference in Washington, DC, USA. The results show that...
ATTRACT results are “a springboard” for future pharmacomechanical thrombolysis research
Data from the randomised controlled ATTRACT trial revealed that the addition of catheter-based intervention to standard-of-care anticoagulation failed to significantly decrease the occurrence of...
Monocusp: A hybrid-autogenous solution for deep venous insufficiency
Most existing surgical options for symptomatic deep venous insufficiency (DVI) with venous stasis ulcers either fail or provide limited success. Many surgeons consider operating...
ATTRACT fails to meet primary endpoint, but experts agree results are “hypothesis-generating”
Data from the randomised controlled ATTRACT trial revealed that the addition of catheter-based intervention to standard-of-care anticoagulation failed to significantly decrease the occurrence of...
The success of deep venous intervention rests on mid- to long-term outcomes
In this interview, Vascular News speaks to Prakash Saha, King’s College Hospital, London, UK, about the growth of deep venous treatment and how the...
Advances and challenges in the treatment of deep vein thrombosis
The goal of management of venous thromboembolic disease is to prevent thrombus extension or embolisation and to prevent early and late episodes of recurrence....
Endothermal heat-induced thrombosis after endovenous laser ablation—a rare complication with safe management
Ovsep Mandzhikian, Moscow, Russia, reports on his centre’s recent experience of endothermal heat-induced thrombosis following treatment with endovenous laser and radial fibres, suggesting that...
Ultrasound-enhanced catheter-directed thrombolysis as the standard of care for acute DVT
Ash Verma, Clearwater, USA, writes how last year, he happened upon a routine case that struck him as both totally unremarkable and absolutely extraordinary....
Key clinical questions I would like to see answered in the future of deep...
Therapies in deep venous thrombosis (DVT) have been slow to advance over the past 50 years. Recently, growing awareness and improvements in tools and...
When to use intervention for deep venous thrombosis and pulmonary embolism
At the 2016 Leipzig Interventional Course meeting (LINC; 26–29 January, Leipzig, Germany), Michael R Jaff, Boston, USA, discussed the challenges facing intervention for deep...
Low rates of major bleeding seen in pivotal trial of rivaroxaban for deep vein...
Bayer and its development partner Janssen Pharmaceuticals presented results from two real world studies—the non-interventional XALIA study in patients with deep vein thrombosis (DVT)...
Catheter-directed thrombolysis for pulmonary embolism in the paediatric population
Peter H Lin
Pulmonary embolism in children is a potentially lethal condition and yet is a vastly understudied arena. Autopsy studies show a higher prevalence...
NICE recommends once-daily Lixiana (edoxaban) to treat and prevent adult recurrent deep vein thrombosis...
The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has recommended a new treatment to help...
SEATTLE II results show no intracranial haemorrhage or no death among pulmonary embolism patients
The study concluded that treatment with ultrasound-facilitated catheter-directed low-dose thrombolysis for acute pulmonary embolism improves right heart function, reduces blood clot size, and decreases pulmonary hypertension in patients with intermediate to high risk pulmonary embolism.
Cancer-associated thrombosis patients 35% less likely to experience thromboembolism when treated with innohep (tinzaparin)...
Results of the landmark CATCH (Comparison of Acute Treatments in Cancer Haemostasis) study were published in The Journal of American Medical Association (JAMA), comparing innohep (tinzaparin),...
NICE publishes final guidance on the use of Eliquis (apixaban) to treat and prevent...
Bristol-Myers Squibb and Pfizer have announced that the National Institute for Health and Care Excellence (NICE) has published final guidance recommending the use of...
NICE publishes final guidance on the use of Eliquis (apixaban) to treat DVT and...
As part of a 90-day implementation plan, the NHS now has three months for apixaban to be made available to patients in England and Wales whose doctors believe it is a clinically appropriate treatment for them.
Use of vena cava filter does not reduce risk of recurrent blood clot for...
Observational studies show a sharp increase in the placement of inferior vena cava filters over the past three decades, including their use as add-on therapy to anticoagulant therapy in patients presenting with a blood clot.
Preliminary data suggest VenaTech convertible filter is a safe and effective temporary filter
Early data from a multicentre, single-arm study that set out to evaluate the safety and effectiveness of a novel approach to inferior vena cava...
What the vascular specialist must know about echo for pulmonary embolism
By David Dudzinski
Transthoracic echocardiography offers real-time information that assists vascular specialists in the diagnostic and prognostic evaluation of acute pulmonary embolism. Specific roles of...
Secondary analysis of AMPLIFY-EXT examining predictors of hospitalisation presented at ESC congress
Bristol-Myers Squibb and Pfizer have announced results of a pre-specified secondary analysis of the Eliquis phase 3 AMPLIFY-EXT trial (Apixaban after the initial management...
European Commission approves Eliquis (apixaban) for treatment of deep vein thrombosis and pulmonary embolism
Bristol‐Myers Squibb Company and Pfizer have announced that the European Commission has approved Eliquis (apixaban) for the treatment of deep vein thrombosis and pulmonary...
Eliquis (apixaban) receives CHMP positive opinion for the treatment of deep vein thrombosis and...
Bristol-Myers Squibb Company and Pfizer have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
EKOS initiates study in patients with chronic deep vein thrombosis and post-thrombotic syndrome
EKOS Corporation has announced the start of patient enrolment for the Accelerated thrombolysis for post-thrombotic syndrome using the EkoSonic endovascular system (ACCESS PTS) study.
The...
FDA clears EkoSonic endovascular system
Ekos Corporation has announced that the US Food and Drug Administration (FDA) has cleared the EkoSonic endovascular system for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism.
ULTIMA trial results published in Circulation
EKOS Corporation announced on 20 January 2014 the publication of the results of its ULTIMA (Ultrasound accelerated thrombolysis of pulmonary embolism) trial in Circulation....
Phase III study of dabigatran meets primary endpoint for six-month treatment of venous thromboembolism
Boehringer Ingelheim has announced results from the RE-COVER II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis and/or...
Increasing filter retrieval rates should be a priority
By Brian G DeRubertis
Surgical caval interruption for prevention of fatal pulmonary embolisation had been performed since the 1950s, though the modern era of pulmonary...
New rotational pharmacomechanical thrombectomy device promising for deep vein thrombosis
A new rotational thrombectomy device is safe and effective in the treatment of acute and subacute deep vein thrombosis in a single session of...
“Filter or no filter” during percutaneous endovenous intervention for deep vein thrombosis
By Mohsen Sharifi
Percutaneous endovenous intervention (PEVI) is increasingly being used in the treatment of massive lower extremity deep vein thrombosis. It utilises a variety...
Advances in drug therapy for the treatment of thrombophlebitis and pulmonary embolism
By Russell Samson
Aspirin finds a role again
Before the advent of more potent heparin, low molecular weight heparins and warfarin, aspirin was used extensively in the...
European commission approves rivaroxaban for the treatment of pulmonary embolism and the prevention of...
Rivaroxaban (Xarelto, Bayer HealthCare) has been approved by the European Commission for the treatment of pulmonary embolism (PE) and the prevention of recurrent deep...
ASPIRE trial shows 34% reduction in major vascular events with aspirin in unprovoked venous...
Low-dose aspirin prevents recurrent venous thromboembolism and major vascular events in patients with first unprovoked venous thromboembolism, results from the ASPIRE randomised controlled trial,...
UK’s NICE consults on new draft quality standard for management of venous thromboembolic diseases
On 3 October, the UK’ National Institute for Health and Clinical Excellence (NICE) opened a consultation on a new draft quality standard for the...
New developments in retrievable inferior vena cava filters reviewed
The new Crux inferior vena cava filter can be implanted and retrieved safely and shows a low rate of pulmonary embolism, Anthony J Comerota,...
Angel Catheter is CE-marked
BiO2 Medical has announced that it has received CE mark approval for the Angel Catheter, a nitinol inferior vena cava (IVC) filter, permanently attached...
EKOS announces two more pulmonary embolism clinical studies
SEATTLE I and II are intended to further establish the safety and efficacy of ultrasound accelerated thrombolysis for treatment of pulmonary embolism.
Percutaneous endovenous intervention effective for upper extremity deep venous thrombosis
Mohsen Sharifi, adjunct associate professor of Medicine at A T Still University, Mesa, USA, presented new data demonstrating that percutaneous endovenous intervention (PEVI) is...
Scottish Medicines Consortium accepts rivaroxaban for NHS use in two new indications in Scotland
The anticoagulant rivaroxaban (Bayer HealthCare, Xarelto) has been accepted by the Scottish Medicines Consortium (SMC) for use in eligible patients within NHS Scotland in...
Are inferior vena cava filters as good as we think in the prevention of...
By Jörn Oliver Balzer
Pulmonary embolism continues to be a major cause of morbidity and mortality in the United States. In most clinical situations, anticoagulation...
Catheter-directed thrombolysis reduces risk of post-thrombotic syndrome in patients with DVT in the lower...
Researchers from Norway have found that additional treatment with catheter-directed thrombolysis (CDT), when compared to standard treatment of oral anticoagulation therapy and elastic compression...
Charles McCollum
Charles McCollum, University of Manchester, UK, became consultant and senior lecturer in Surgery at the Charing Cross Hospital, London, UK, in 1983, aged 32....
Management of deep vein thrombosis
DVT, other than that triggered by trauma or surgery, is now considered to be a chronic disease with a high risk of recurrence.
‘Rapid lysis’ technique could potentially change DVT treatment
Results at the Society of Interventional Radiology's 32nd Annual Scientific Meeting, in Seattle, WA, Dr Mark J Garcia.
